Biotage – alleged patent infringement settled - correction

In the press release with the heading “Biotage – alleged patent infringement settled” published earlier today, reference was by mistake made to the EU Market Abuse Regulation and the Securities Markets Act in the label of the press release. Since the information was not regarded as insider information the reference should not have been included.

Contact persons:                        
Torben Jörgensen, CEO                        
Tel: 0707-49 05 84, torben.jorgensen@biotage.com


This information was submitted for publication, through the agency of the contact persons set out above, at 11.00 CET on August 16, 2017.

About Biotage
Biotage offers efficient separation technologies from analysis to industrial scale and high quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage’s products are used by government authorities, academic institutions, pharmaceutical and food companies, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan and South Korea. Biotage has approx. 330 employees and had sales of 667 MSEK in 2016. Biotage is listed on the NASDAQ OMX Nordic. Website: www.biotage.com

Tags:

About Us

Biotage offers efficient separation technologies from analysis to industrial-scale and high-quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage’s products are used by public authorities, academic institutions, contract research and contract manufacturing organizations and in the pharmaceutical and food industries, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan, South Korea and India. Biotage has approx. 390 employees and had sales of 748 MSEK in 2017. Biotage is listed on Nasdaq Stockholm. Website: www.biotage.com

Subscribe

Documents & Links